Table 2.
Subgroup analysis of the effect on all-cause mortality
| Subgroup | No. of studies | COMBO (events/total) | STAN (events/total) | Risk ratio (95% CI) | P value | I2% |
|---|---|---|---|---|---|---|
| Year of publication | ||||||
| Before 2006 | 6 | 14/143 | 13/139 | 0.89 (0.43–1.86) | 0.76 | 4 |
| In or after 2006 | 8 | 177/1022 | 185/1056 | 1.01 (0.84–1.22) | 0.93 | 0 |
| Number of patients | ||||||
| ≥ 200 | 4 | 144/847 | 141/872 | 1.05 (0.85–1.30) | 0.66 | 0 |
| < 200 | 10 | 47/318 | 57/323 | 0.87 (0.61–1.25) | 0.46 | 0 |
| Adjuvant agents | ||||||
| BLs | 2 | 40/201 | 34/203 | 1.19 (0.78–1.80) | 0.42 | 0 |
| Fosfomycin | 1 | 18/74 | 22/81 | 0.90 (0.52–1.53) | 0.69 | – |
| Daptomycin | 1 | 10/53 | 9/51 | 1.07 (0.47–2.41) | 0.87 | – |
| Ceftaroline | 1 | 0/17 | 7/23 | 0.09 (0.01–1.46) | 0.09 | – |
| Rifampin | 5 | 102/678 | 87/501 | 0.66 (0.37–1.19) | 0.17 | 66 |
| Levofloxacin | 1 | 34/191 | 39/190 | 0.87 (0.57–1.31) | 0.50 | – |
| Gentamicin | 4 | 27/216 | 21/212 | 1.24 (0.73–2.13) | 0.43 | 0 |
STAN standard treatment, COMBO combination treatment, BLs β-lactam antibiotics